Data / Form D filings / Focal Point Pharmaceuticals, Inc.
Focal Point Pharmaceuticals, Inc.: Form D filings
Focal Point Pharmaceuticals, Inc., a pharmaceuticals company in Memphis, TN, filed 3 Form D notices with the SEC between 2013 and 2017. The latest, on January 31, 2017, reports $80,000 sold of a $80,000 offering to 2 investors.
Find out what Focal Point Pharmaceuticals, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 40 S. MAIN ST., STE. 2200, Memphis, TN, 38103
- Phone
- (484) 680-5222
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2013
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1584237
The full lists. Form D filings in Tennessee: 543 rows, $27.15, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jan 31, 2017 | Amendment | $80,000 | $80,000 | $0 | 2 | Jan 30, 2017 | sec.gov |
| Jan 31, 2017 | New notice | $80,000 | $80,000 | $0 | 2 | Jan 30, 2017 | sec.gov |
| Aug 14, 2013 | New notice | $150,000 | $150,000 | $0 | 2 | Aug 12, 2013 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Raymond Hage | Executive Officer, Director | |
| Gary Stevenson | Director | |
| Gary Prosterman | Executive Officer, Director |
Every Form D from the week of Jan 30, 2017 · All recent filings in Tennessee · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Focal Point Pharmaceuticals, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.